• Novartis picks Precision Bio to bring in vivo gene editing meds to blood disorders

    8 days ago - By MedCity News

    Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, such as sickle cell disease. One of the goals of the alliance is to make genetic medicines more globally accessible.
    Read more ...